Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of the use of inhalational heparin in patients with
pulmonary compromise / pneumonia / SARS associated with COVID-19, laboratory with marked
inflammation parameters, and prothrombotic state secondary to it (Fibrinogen, Ferritin and /
or elevated D-Dimer) , from admission to hospitalization.
The combination of inhalation heparin combined with prophylactic doses of LMWH could reduce
the progression to severe forms of the disease, and consequently the need for intensive care
units and mechanical ventilation.